Glenmark Pharmaceuticals Ltd. (Glenmark), is a research-led, global pharmaceutical company, has received final approval by the United States Food & Drug Administration (FDA) for apremilast tablets, 10 mg, 20 mg and 30 mg, the generic version of Otezla tablets, 10 mg, 20 mg and 30 mg, of Amgen Inc.
Glenmark’s current portfolio consists of 188 products authorized for distribution in the US marketplace and 50 ANDA’s pending approval with the US FDA. In addition to these internal filings,
Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.
Glenmark Pharmaceuticals Limited is a research-led, global pharmaceutical company, having a presence across branded, generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology and oncology. The company has 10 world-class manufacturing facilities spread across 4 continents, and operations in over 80 countries.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!